Uterine Fibroids — Body Handbook

Healthcare · §671

Uterine Fibroids

By age 50, roughly seven in ten white women and more than eight in ten Black women have at least one fibroid — benign muscle growths in the wall of the uterus. Most stay quiet. About a quarter become the reason for a hysterectomy, the second-most-common operation done on women in the US. The interesting story sits between those numbers: the modern menu of pills, IUDs, embolization, and uterus-sparing surgery now lets most women keep their uterus and still fix the problem — but only if the right option is matched to where the fibroid sits and what the woman actually wants.

Decide · As-needed Evidence Strong Chapter Healthcare

The bleeding is the symptom most women normalize and shouldn't — heavy fibroid periods quietly drain iron and cost real energy, focus, and mood, all of which come back once the bleeding is fixed. Treatment is well-evidenced and well-tiered: an oral once-daily drug or hormonal IUD for bleeding alone, a same-day hysteroscopic resection for fibroids inside the cavity, embolization or uterus-preserving surgery for bulky disease, hysterectomy as the definitive option for women done with childbearing. The catch is cost and recovery — most options run several thousand dollars and weeks of downtime, and the right pick depends on fibroid location and reproductive plans more than on doctor preference.

A fibroid is a single muscle cell in the wall of the uterus that started copying itself and didn't stop. Each one is a clone — one cell's worth of growth, even if your uterus ends up with twenty of them. They are not cancer, they are not pre-cancer, and they almost never turn into cancer. They are just the most common tumor that a uterus makes, and they make them on purpose: estrogen and progesterone — the hormones that drive your period — are the same hormones that feed fibroids (Bulun 2024).

Three things follow from that. First, fibroids are a reproductive-years problem: they don't form before puberty, and they shrink and quiet down after menopause. Second, whatever stops the hormonal signal — pregnancy in some cases, menopause in nearly all — also stops the fibroid. Third, the location matters more than the size. A small fibroid pushing into the cavity of the uterus bleeds heavily; a large fibroid sitting on the outside surface presses on the bladder but barely affects periods. The same lump in two different locations gives two completely different lives.

Underneath, the genetics are surprisingly tidy. Most fibroids — about seven in ten — carry the same mutation in a gene called MED12, which makes the cell extra-sensitive to progesterone (Bulun 2024). That sensitivity is why hormonal therapies work, and it's also why the same fibroid can stay stable for years and then suddenly grow during a perimenopausal hormone surge or shrink during nursing. The driver is the ovary; the fibroid just hears the signal louder than the rest of the uterus does.

What we actually know

The most replicated finding is the prevalence and the disparity. Two-thirds to four-fifths of women have at least one fibroid by 50, depending on the population sampled, and Black women carry both the higher prevalence and the earlier onset — roughly a decade earlier than white women (Baird et al. 2003) (Stewart et al. 2017). Most of these fibroids never become symptomatic. The ones that do tend to declare themselves through heavy menstrual bleeding, pelvic pressure, or a fertility delay, and those are the ones that get treated.

On treatment, the bar of evidence is unusually high for gynecology. The newest medical option — once-daily oral GnRH antagonist combinations — went through three independent Phase 3 trial programs, and they all read the same: roughly seven in ten women hit a 50%+ drop in bleeding within six months, versus one in ten on placebo, with bone density preserved by the estrogen add-back built into the pill (Al-Hendy et al. 2021) (Schlaff et al. 2020) (Simon et al. 2022).

The procedural side is also well-studied. The FEMME trial directly compared myomectomy (surgical fibroid removal) with uterine artery embolization (interventional radiology blocks the fibroid's blood supply) in 254 UK women who wanted to keep their uterus (Manyonda et al. 2020). Both worked; quality-of-life scores roughly doubled in each group at two years, with a modest edge to myomectomy (8 points on a 100-point scale). The EMMY trial, comparing embolization to hysterectomy, followed 177 Dutch women for ten years and found that two-thirds of the embolization group avoided hysterectomy entirely while reporting the same quality of life as the hysterectomy group (de Bruijn et al. 2016). Hysterectomy itself remains 100% effective by definition — no uterus, no fibroids — and accounts for about 40% of all fibroid treatment in the US (ACOG 2021).

Where the evidence thins out is the pregnancy question — what happens to fertility and to obstetric outcomes after each intervention. Hysteroscopic removal of fibroids sitting inside the cavity roughly doubles natural pregnancy rates in women who couldn't conceive before (Pritts et al. 2009); outside that specific case, the data on whether removing fibroids helps fertility is much weaker.

What you live with if you ignore it

The honest answer is: usually nothing. Most fibroids never declare themselves and are found incidentally on an ultrasound done for something else. Watchful waiting is a legitimate strategy for a small fibroid that isn't causing problems, and for a perimenopausal woman within a few years of menopause whose periods are getting closer to ending anyway.

But if you've landed here because something is actually wrong, the typical trajectory of an untreated symptomatic fibroid runs along three quiet rails. The first is bleeding. Heavy fibroid periods don't usually feel like an emergency — they feel like "my periods are just heavy" — but the iron loss is real and it accumulates. About a third of women with symptomatic fibroids develop iron-deficiency anemia (ACOG 2021), and the version of you with chronically low iron is the one who's tired by 3pm, who can't get through a workout that used to be easy, who sheds more hair than seems normal, who has restless legs at night and brain fog at meetings. People around you stop expecting you to be the energetic one. You stop expecting it of yourself. Most of this gets blamed on stress, age, or motherhood until somebody checks a ferritin level — and the drain often bites well before the count formally reads as anemia. Replacing the iron is a lever in its own right: it brings the energy back while you sort out the bleeding, not only after.

The second rail is bulk. A small fibroid in the wall of the uterus doesn't take up space; a 10- or 15-cm fibroid does. The uterus enlarges to roughly the size of a 14-week pregnancy and starts displacing the bladder above it and the rectum behind it. Urinary frequency that wakes you twice a night, constipation that wasn't there a year ago, a lower abdomen that pushes against waistbands the way it didn't in your 20s — these are mechanical, not hormonal, and they don't improve with diet or pelvic floor work.

The third rail is the slow narrowing of the menu. Fibroids that were small enough for an outpatient hysteroscopic removal at 35 may be too large and too numerous for the same procedure at 42. The patient with a uterus full of multiple fibroids who finally presents at 45 with severe anemia is the patient for whom hysterectomy starts to look like the easiest answer — and that's exactly why hysterectomy accounts for the plurality of US fibroid treatments. The uterus-sparing menu narrows by the time many women reach it.

How treatment is actually chosen

Two questions decide almost everything. Where is the fibroid? (cavity, wall, or outer surface) and do you still want the option of pregnancy? Layer the symptom — bleeding, bulk, or both — on top of those two, and the menu collapses to one or two reasonable choices. Current ACOG guidance is to start medical, escalate to procedural only when medical fails or the anatomy demands it, and reserve hysterectomy for definitive cases (ACOG 2021).

If bleeding is the main problem

Tranexamic acid, 1.3 g three times daily only on heavy days, for up to 5 days per cycle. Non-hormonal, taken only as needed, cuts blood loss by roughly a third to a half. First choice if your cavity is normal and you just want less bleeding.
Hormonal IUD (the 52-mg levonorgestrel coil — Mirena, Liletta). Inserted in a clinic visit, works for 5–8 years, often stops periods entirely. Works less well if a fibroid distorts the cavity and is more likely to fall out in that setting.
Oral GnRH antagonist combination (relugolix/Myfembree, elagolix/Oriahnn, linzagolix/Yselty). One pill daily; reduces bleeding by 50%+ in about 70% of users within six months (Al-Hendy et al. 2021). Approved for up to 2 years of continuous use. Expensive without insurance.
Hysteroscopic myomectomy if a fibroid is actually inside the cavity (FIGO 0, 1, or 2). Same-day outpatient procedure through the cervix, no abdominal incision, resolves heavy bleeding in 70–80% of cases and is also the fibroid intervention that most clearly improves fertility (Pritts et al. 2009).

If bulk and pressure are the main problem

Myomectomy — surgical removal of the fibroids while leaving the uterus intact. Done laparoscopically (or robotically) for moderately-sized fibroids and as an open surgery for very large or numerous ones. The default choice if you want to preserve fertility.
Uterine artery embolization (UAE) — an interventional radiologist threads a catheter into the uterine artery and injects tiny particles that cut off blood supply to the fibroids; they shrink over months. Shorter recovery than myomectomy (about a week vs. several weeks), modestly lower long-term quality-of-life gains (Manyonda et al. 2020), and not the first choice if pregnancy is on the table.
Radiofrequency or ultrasound ablation (Acessa, Sonata, MR-guided focused ultrasound). Heat-based, uterus-preserving, shorter recovery; less long-term data and fewer pregnancy outcomes published.
Hysterectomy — removes the uterus and ends the problem permanently. Done laparoscopically, vaginally, or open depending on uterine size. The right answer when childbearing is finished and other approaches have failed or the disease is too extensive for uterus-sparing options.

A common bridge is a short course of GnRH agonist (leuprolide) injections for 2–3 months before surgery — fibroids shrink ~40%, anemia corrects, and the operation becomes easier and safer. Useful preoperatively, not as a long-term strategy because of bone loss without add-back hormones.

If pregnancy is on the table

Fertility is the place where fibroid location matters most and where the evidence is cleanest. A fibroid that pushes into the cavity — FIGO type 0, 1, or 2 — interferes with implantation, increases miscarriage risk, and is one of the few situations where removing the fibroid clearly improves the odds of getting and staying pregnant. Hysteroscopic removal of these cavity-distorting fibroids roughly doubles natural pregnancy rates in women who couldn't conceive before (Pritts et al. 2009). ASRM's 2017 guidance is to remove cavity-distorting fibroids in the workup of unexplained infertility (ASRM 2017).

For fibroids sitting in the muscle wall without touching the cavity, the picture blurs. Large intramural fibroids (over about 4 cm) probably reduce IVF success modestly; smaller ones probably don't. Outer-surface (subserosal) fibroids don't appear to affect fertility at all. Whether to remove a non-cavity-distorting fibroid before pregnancy is a judgment call that should weigh the recovery time, the cesarean-required-for-future-delivery risk, and the likelihood that the fibroid was actually the problem.

In pregnancy itself, most fibroids are uneventful — they may grow modestly in the first trimester and then plateau. The main pregnancy-specific complication is red degeneration, a sudden infarction-like pain in a fibroid that's outgrown its blood supply; it resolves with rest and analgesics and is not dangerous to the pregnancy. A large meta-analysis of 237,509 pregnancies showed that fibroids do modestly raise the risk of preterm birth, cesarean delivery, placenta previa, miscarriage, and postpartum hemorrhage (Li et al. 2024). The absolute risks remain low for most women.

If you're Black

The disease is different in degree and timing. Compared with white women, Black women develop fibroids about a decade earlier, present with larger and more numerous fibroids, and are more likely to end up with a hysterectomy rather than a uterus-sparing procedure for the same underlying disease (Baird et al. 2003) (Stewart et al. 2017). The Study of Environment, Lifestyle and Fibroids — a prospective ultrasound study in young Black women — confirmed the earlier-onset signal independent of healthcare access, with new fibroids appearing starting in the mid-20s in women who had no idea they had them (Baird et al. 2020).

The practical implication: if you have a first-degree relative with symptomatic fibroids or a hysterectomy for fibroids, the window for catching them early enough for uterus-sparing treatment is your late 20s and 30s, not your 40s. A baseline pelvic ultrasound when heavy periods start — or by age 30 with a strong family history — is reasonable. And because published data show Black women are less often offered uterus-sparing alternatives, naming the options (myomectomy, embolization, GnRH-antagonist combo) by name in the appointment changes the menu that gets discussed.

What most people get wrong

"Fibroids turn into cancer." They don't. Fibroids and uterine sarcomas (the malignant smooth-muscle tumors of the uterus) appear to be biologically distinct from the start; a fibroid does not "transform" over time. The reason cancer comes up in fibroid surgery is a different problem: roughly 1 in 350–500 surgeries done for a presumed fibroid turns out to contain a hidden sarcoma the imaging missed (FDA 2020). That's why the FDA restricted uncontained power morcellation in 2014 — not because fibroids are pre-cancer, but because chopping up a hidden cancer to remove it through small incisions spreads it.

"You need a hysterectomy if it's large or you have several." Twenty years ago, sometimes true. Today, women with 10+ cm fibroids and multiple lesions routinely keep their uterus through myomectomy or embolization. The size and number drive how the procedure is done — laparoscopic vs. open, single-stage vs. preoperative GnRH-agonist shrinkage — but rarely force a hysterectomy on someone who wants the option of pregnancy.

"The birth control pill will make fibroids grow." Combined hormonal contraception at standard doses does not stimulate fibroid growth and is a reasonable option for controlling heavy bleeding (ACOG 2021). The old worry came from extrapolating high-dose 1960s formulations; current low-dose pills don't replicate that signal.

"Fibroids always shrink at menopause, so just wait." Mostly true for white women, less true for Black women, and not true on any predictable timeline. Some fibroids grow in perimenopause as hormones swing before they settle. "Wait it out" is a fine plan if your anemia is manageable and menopause is two years away; it's a poor plan if you're 38 with three children's worth of blood loss every month.

"Diet caused this — fix the diet, fix the fibroids." Obesity, vitamin D deficiency, and heavy alcohol use are associated with higher fibroid risk in observational studies, and a green-tea compound called EGCG has shown some experimental effect on fibroid cells. But there is no diet that reliably shrinks an existing fibroid, and no intervention trial has shown that changing diet treats symptoms. Lifestyle is reasonable prevention; it is not treatment.

What it costs, what it takes

The diagnostic side is cheap and accessible. A transvaginal ultrasound — usually $200–$500 out of pocket, often fully covered by insurance — finds essentially every clinically significant fibroid (ACOG 2021). If the doctor wants to see exactly which fibroids sit inside the cavity, a saline-infusion sonohysterography adds an in-office step that runs another $200–$400. An MRI ($1,000–$2,000) is reserved for surgical planning when the uterus is large or there are many fibroids.

The treatment side is where the bill compounds. In US dollars, a typical year of intervention runs:

Tranexamic acid — about $30–$60 per cycle generic; the cheapest sustained therapy.
Hormonal IUD — $500–$1,300 with insertion; lasts 5–8 years, so $80–$250/year amortized.
GnRH antagonist combination pills — $800–$1,000+ per month without insurance; can drop sharply with coverage and copay cards.
Hysteroscopic myomectomy — $3,000–$8,000 facility plus surgeon fees; same-day outpatient.
Uterine artery embolization — $5,400–$7,600 all-in; 1–2 days in hospital, 1–2 weeks recovery.
Laparoscopic or open myomectomy — $5,400–$11,800; 2–6 weeks recovery depending on approach.
Hysterectomy — $5,000–$8,000; 2–6 weeks recovery; one-time, permanent (Soliman et al. 2015).

The hidden cost is the part that doesn't show up on the bill. Symptomatic fibroid disease costs the average affected woman $2,200–$16,000 a year in lost work, sick days, and reduced household productivity; 60% of symptomatic women say it impairs physical activity, and a quarter say it stops them from reaching their potential at work (Soliman et al. 2015). National direct medical costs run $5.9–34.4 billion a year in the US (ACOG 2021). The intervention that fixes the symptom usually pays for itself within a year against the lost productivity it ends.

Where the menu fails in practice

The bleeding gets normalized for years. The single most common failure mode isn't a treatment that didn't work — it's a treatment that never got considered. Heavy periods are so often dismissed by patients ("my mom's were like this too") and by clinicians ("everyone's bleeding heavy is a little different") that the diagnostic ultrasound waits a decade. By the time someone runs a ferritin level, the woman has been anemic for years. The fix is dumb but real: if you're going through a super pad or tampon faster than every two hours, soaking through clothing, passing clots larger than a quarter, or skipping plans because of your period, ask for a ferritin and a pelvic ultrasound.

The IUD gets expelled. A levonorgestrel IUD works beautifully if the uterine cavity is normal. If a submucosal fibroid is distorting the cavity, the device tends to fall out — sometimes silently. Imaging the cavity (saline sonohysterogram) before insertion in a woman with known fibroids is the prevention. If it's coming out, fix the fibroid first, then place the IUD.

The wrong procedure for the wrong fibroid. Hysteroscopic myomectomy only reaches fibroids inside or nearly inside the cavity. A subserosal fibroid on the outer wall isn't reachable through the cervix; trying to bend the procedure to fit it leads to incomplete removal and persistent symptoms. The matched-procedure problem runs both ways: laparoscopic myomectomy of a true cavity-distorting submucosal fibroid is more invasive than needed. Pre-procedure imaging — usually MRI for surgical planning — is what gets the procedure matched to the anatomy.

New fibroids after myomectomy. Removing the visible fibroids doesn't change the underlying biology of the uterus. About 15–30% of women develop new symptomatic fibroids over the following 5–10 years. This isn't a procedural failure; it's a feature of the disease. The conversation at the time of myomectomy should include this number, especially for young women — sometimes it nudges the calculus toward UAE (which treats the whole uterus at once) or toward completing childbearing before considering further intervention.

The hidden sarcoma. Roughly 1 in 350–500 surgeries for a presumed fibroid turns out to contain an occult uterine sarcoma (FDA 2020). The risk rises with age, especially after menopause. This is why power morcellation in older women is now contained (in a bag) or avoided entirely, and why a fibroid that's growing rapidly in a postmenopausal woman is treated as cancer until proven otherwise.

What changes when you treat it

The bleeding piece comes back fastest. On a GnRH-antagonist combination pill, the typical timeline is a 50%+ reduction in menstrual blood loss within two cycles and continued improvement through six months (Al-Hendy et al. 2021). With an LNG-IUS, most women see substantial bleeding reduction by the third or fourth cycle. After a hysteroscopic myomectomy, the next period after recovery is usually noticeably lighter, and most women describe the change as "I forgot I used to bring extra clothes to work." The downstream effect of the bleeding fix is iron repletion: ferritin starts rebuilding within weeks, hemoglobin normalizes over two to three months, and the energy and concentration changes lag the hemoglobin by a few weeks more. By six months out, the version of you that ran a low-grade exhaustion is gone and people stop asking if you're feeling okay.

The bulk piece is slower. After UAE, fibroids shrink ~40% over three to six months; the abdominal pressure ease shows up gradually across that window. After myomectomy or hysterectomy, the change is immediate — the uterus is the size it should be the day you wake up — but recovery from the surgery itself takes 2–6 weeks before you feel the gain. Either way, the "I look pregnant" complaint resolves, and the urinary frequency that woke you twice a night stops.

Two years out, UFS-QOL quality-of-life scores roughly double across all the major interventions (Manyonda et al. 2020). Ten years out, the picture is durable: two-thirds of women who chose embolization have not needed any further fibroid procedure, and women who chose hysterectomy never need one (de Bruijn et al. 2016). New fibroids do develop in 15–30% of myomectomy patients over the same window, but most are smaller and don't require re-intervention.

The longest-horizon payoff is menopause itself. The hormone-dependent biology that drove the fibroid for 20–30 years switches off; existing fibroids regress, and new ones essentially don't form. The bleeding is over by definition once periods stop. For a 47-year-old with manageable anemia and patience, "wait two years" is genuinely a treatment plan.

Adjacent topics worth a look

Heavy menstrual bleeding from non-fibroid causes — clotting disorders, endometrial polyps, hormonal imbalance, adenomyosis. Same symptom, different workup, often missed when a fibroid is assumed to be the explanation.
Iron-deficiency anemia — the downstream consequence of years of heavy bleeding, often the thing actually making you tired. Worth its own ferritin check and repletion plan, regardless of what's causing the bleeding.
Adenomyosis — endometrial tissue inside the uterine muscle wall, frequently co-existent with fibroids and easy to confuse on imaging; the treatment menu overlaps but isn't identical.
Endometriosis — endometrial tissue outside the uterus, with overlapping pelvic-pain symptoms but a completely different mechanism and management.
Menopause and hormone therapy — fibroids regress naturally as ovarian hormones decline; standard postmenopausal hormone therapy doses don't typically reactivate them.

Related in the handbook

Worsens / aggravates

— Heavy fibroid bleeding quietly drains iron; the tiredness and brain fog often trace back to that, not the fibroid itself.

Helps

— A hormonal IUD is a first-line fix for the bleeding when the fibroid doesn't sit inside the cavity.
— Heavy fibroid periods quietly drain your iron for years. Replacing it is often what brings the energy back while you sort the bleeding.

Diagnosis

— Heavy fibroid periods quietly drain your iron stores for years; a ferritin and TSAT check shows how deep the hole is before you feel the fatigue.
— Tracking how heavy and how long your periods run turns 'my periods are bad' into the kind of record that gets fibroids taken seriously.

— Heavy periods are the symptom most fibroids announce themselves with, and the one most worth not normalizing.
— Adenomyosis causes the same heavy painful periods and often coexists; the ultrasound distinguishes them.
— Like endometriosis, fibroids drive heavy painful periods; the symptom overlap is why imaging matters.
— Fibroids feed on the same hormones your period runs on, so they can flare during the perimenopausal surge and quiet down after menopause.

Substance and claimed effects

Uterine fibroids (leiomyomas, myomas) are benign monoclonal tumors of uterine smooth muscle, the most common pelvic neoplasm in people with a uterus. Ultrasound-based screening puts cumulative incidence by age 50 at ~70% in white women and >80% in Black women (Baird et al. 2003), with prevalence estimates spanning 4.5–68.6% depending on population and ascertainment method (Stewart et al. 2017). Approximately 25% of women with fibroids develop symptoms severe enough to warrant treatment; the dominant phenotypes are heavy menstrual bleeding (HMB) with secondary iron-deficiency anemia, bulk/pressure symptoms (urinary frequency, constipation, dyspareunia, abdominal distention), and reproductive/obstetric morbidity (ACOG 2021). Consequences this entry covers holistically: short-term health (HMB/anemia, pelvic pressure, pain), mood (psychological burden of HMB and chronic anemia), beauty (visible abdominal distention with bulky disease; anemia-driven pallor), fertility and pregnancy outcomes, longevity (very modest — fibroids are not lethal but morcellation of an occult sarcoma is), and the high cost/effort burden of definitive treatment. The article is anchored on location-stratified management (FIGO 0–8), because the same diagnosis produces very different clinical pictures and treatment menus depending on where the fibroid sits.

Evidence by addressing question

mechanism

Cellular origin and hormonal dependency. Each fibroid is a clonal expansion from a single myometrial smooth-muscle precursor, driven by ovarian steroids. Estradiol primes the tissue and upregulates progesterone receptors; progesterone — acting through PR on mature fibroid cells — is the dominant proliferative signal, working partly through paracrine release of WNT ligands, RANKL, EGF, and TGF-β3 onto adjacent stem cells (Bulun et al. 2024). Both the mutated myocytes and tumor-associated fibroblasts lay down excessive extracellular matrix, which is why these tumors are firm and disproportionately heavy for their cellular content.

Genetic drivers. Somatic gain-of-function mutations in MED12 (a subunit of the Mediator transcriptional co-activator complex) are present in 50–80% of fibroids and are the single most common driver lesion. HMGA2 rearrangements account for another ~10%, and germline FH mutations underlie hereditary leiomyomatosis and renal cell carcinoma (HLRCC) (Bulun et al. 2024). MED12-mutant tumors disrupt CDK8/19 kinase activity in the Mediator complex, dysregulate Wnt/β-catenin signaling, and show heightened progesterone responsiveness — likely explaining why GnRH-based therapies and ulipristal acetate shrink some fibroids and not others depending on mutation status.

Why HMB happens. Submucosal and cavity-distorting fibroids increase endometrial surface area, deform the endometrial-myometrial junction, and produce local TGF-β3 that disrupts BMP-2-mediated endometrial hemostasis. The result: prolonged, heavy, often clot-laden menses that anatomy-blind hormonal therapy can only partly suppress (ACOG 2021).

evidence

Diagnosis. Transvaginal ultrasound is first-line, with reported sensitivity of ~90–99% for any fibroid and ~90% sensitivity/98% specificity for submucosal disease; saline-infusion sonohysterography achieves 98–100% sensitivity/specificity for distinguishing FIGO types 0/1/2 and is cheaper than hysteroscopy. MRI is the most accurate modality for mapping fibroid number, size, and location and is reserved for surgical planning, an enlarged uterus that escapes the ultrasound field, or before uterine artery embolization to confirm vascular supply (Munro et al. 2018) (ACOG 2021).

FIGO classification (Munro 2011, revised 2018). Types 0–2 are submucosal (intracavitary to ≥50% intramural with cavity projection); 3–4 are intramural; 5–7 are subserosal; 8 is "other" (cervical, parasitic, broad ligament). Type 3 abuts the endometrium without invading the cavity; type 7 is pedunculated outside the uterus. Hybrid descriptors (e.g., "2–5") capture transmural lesions. The classification is treatment-determining: submucosal disease drives bleeding and is best resected hysteroscopically; subserosal disease drives bulk and is the easier target for embolization or laparoscopic myomectomy (Munro et al. 2018).

Medical therapies for HMB. Multiple modalities have RCT support, with effect sizes that depend on whether bleeding is the dominant complaint:

Tranexamic acid (1.3 g three times daily, days of heaviest flow): non-hormonal antifibrinolytic; reduces menstrual blood loss by ~30–50% in HMB generally; ACOG-endorsed first-line for fibroid-related HMB (ACOG 2021).
LNG-IUS (52-mg levonorgestrel IUD): substantially reduces HMB and improves quality of life in fibroid patients with non-distorted cavities; does not shrink fibroids; expulsion rates are higher than in non-fibroid users (~10–20% in some series) (ACOG 2021).
Combined oral contraceptives: modest bleeding reduction; do not stimulate fibroid growth at typical doses despite earlier concern.
Oral GnRH antagonists with hormonal add-back: relugolix+E2+NETA met the <80 mL/>50% reduction primary endpoint in 73% (LIBERTY 1) and 71% (LIBERTY 2) of women vs. ~19% on placebo, with preserved bone mineral density at 24 weeks (Al-Hendy et al. 2021). Elagolix+add-back showed comparable response rates (68.5% UF-1, 76.5% UF-2 vs. ~9% placebo) (Schlaff et al. 2020). Linzagolix with add-back replicated this in PRIMROSE 1 and 2 (Simon et al. 2022). All three are now approved (relugolix combo as Myfembree/Ryeqo; elagolix combo as Oriahnn; linzagolix as Yselty in EU) for symptomatic fibroids in premenopausal women.
GnRH agonists (leuprolide): pre-surgical use shrinks fibroid volume ~35–60% and corrects anemia over 3–6 months; vasomotor side effects and bone loss limit duration to ~6 months without add-back.

Procedural and surgical interventions.

Hysteroscopic myomectomy for FIGO 0/1/2 — gold standard for cavity-distorting bleeding fibroids; outpatient, no abdominal incision; effect on HMB durable in 70–80% at 5 years.
Laparoscopic/robotic or abdominal myomectomy for symptomatic intramural/subserosal disease in uterus-sparing patients. The FEMME trial (n=254, UK) randomized symptomatic uterus-preserving patients to myomectomy vs. uterine artery embolization (UAE); at 2 years UFS-QOL improvement was 8.0 points greater with myomectomy (95% CI 1.8–14.1) (Manyonda et al. 2020). New fibroids develop in 15–30% over 5 years; pregnancy is possible but typically requires cesarean delivery for uterine integrity concerns.
Uterine artery embolization — interventional radiology procedure infarcting fibroid blood supply; shorter hospital stay (median 2 vs. 5 days), faster return to activity, comparable quality-of-life gains over the long term. The EMMY trial (UAE vs. hysterectomy, n=177) followed patients 10 years: two-thirds of UAE patients avoided hysterectomy, with comparable health-related quality of life at decade (de Bruijn et al. 2016). Reintervention rates are higher than after myomectomy (~15–30% over 5–10 years).
Hysterectomy — definitive: zero recurrence, no fibroids ever again. Fibroids are the leading indication for hysterectomy in the US, accounting for ~40% of the procedures (ACOG 2021). Removes pregnancy option permanently.
Radiofrequency ablation (Acessa, Sonata) and MR-guided focused ultrasound (MRgFUS) — newer uterus-sparing thermal ablation options; shorter-term data than myomectomy/UAE; uterine integrity for future pregnancy not as well-established.

protocol

ACOG 2021 management is decision-tree shaped by location, symptom phenotype, and reproductive intent. For HMB without bulk symptoms: trial tranexamic acid (1.3 g po three times daily during menses, up to 5 days/cycle for 6 cycles) and/or LNG-IUS first; escalate to a GnRH antagonist combo if bleeding remains uncontrolled or anemia persists. For submucosal disease with HMB: hysteroscopic myomectomy. For bulky disease with bulk symptoms in a patient who wants her uterus: myomectomy (preferred if fertility is desired) or UAE (if not). For a patient finished with childbearing and refractory to medical therapy: hysterectomy is the most durable answer. GnRH agonists are commonly used for 2–3 months before myomectomy or hysterectomy to shrink fibroid volume and correct anemia preoperatively (ACOG 2021).

fertility / pregnancy (under audience + stakes)

Fertility. The clean signal in the literature is that submucosal fibroids of any size and intramural fibroids that distort the cavity reduce implantation, clinical pregnancy, and ongoing pregnancy rates in ART; hysteroscopic resection of submucosal fibroids roughly doubles clinical pregnancy rates (RR 2.03, 95% CI 1.08–3.82) (Pritts et al. 2009). Non-cavity-distorting intramural fibroids >4 cm have a smaller but probably real negative effect; subserosal fibroids do not appear to affect fertility. ASRM 2017 guidance: hysteroscopic myomectomy for cavity-distorting submucosal fibroids improves clinical pregnancy rates; myomectomy may be considered for asymptomatic cavity-distorting fibroids in patients optimizing for pregnancy. Evidence for impact on live birth and miscarriage rates after myomectomy is weaker (ASRM 2017).

Pregnancy. A 2024 meta-analysis (24 studies, n=237,509) found fibroids raise risk of preterm birth, cesarean delivery, placenta previa, miscarriage, PPROM, placental abruption, postpartum hemorrhage, fetal malposition, IUFD, low birth weight, breech, and preeclampsia (Li et al. 2024). Most pregnancies with fibroids proceed without complications; risk concentrates in large fibroids, retroplacental location, and multiple fibroids. Fibroid growth during pregnancy is non-linear, greatest in the first 7 weeks. Red degeneration (acute infarction-like pain) is the most common pregnancy-specific complication.

contraindications

GnRH antagonist combinations are contraindicated in pregnancy and breastfeeding, in known/suspected hormone-sensitive cancers, and in osteoporosis. LNG-IUS expulsion risk is elevated when the cavity is distorted by submucosal fibroids; insertion should generally follow imaging confirmation that the cavity is regular. UAE is generally avoided in patients actively pursuing pregnancy (data on subsequent fertility are limited and pregnancy rates appear lower than after myomectomy in the few comparative trials). Power morcellation during minimally invasive surgery carries a small but documented risk of disseminating occult uterine sarcoma; the FDA estimated occult leiomyosarcoma prevalence at ~1/352–1/498 among surgeries for presumed fibroids and now recommends contained morcellation only, with avoidance of morcellation entirely in perimenopausal and postmenopausal women given the rising sarcoma incidence with age (FDA 2020).

misconceptions

Common misconceptions worth correcting: (1) "Fibroids always grow until menopause" — Peddada et al. demonstrated heterogeneous growth, with individual fibroids in the same uterus growing at different rates, and even spontaneous regression in premenopausal women (Peddada et al. 2008); (2) "Fibroids cause cancer" — leiomyomas do not transform into leiomyosarcomas, which are biologically distinct; the morcellation risk is about missed occult sarcoma at the time of surgery, not malignant degeneration (FDA 2020); (3) "Estrogen-containing contraception worsens fibroids" — combined OCPs and patches do not stimulate growth at typical contraceptive doses and are reasonable for HMB control (ACOG 2021); (4) "Hysterectomy is the only real cure" — for women who finish childbearing and want one definitive procedure, this is true, but uterus-sparing options (myomectomy, UAE, ablation) are effective for the symptom problem in most women.

audience

Race. Black women experience clinically significant fibroid disease ~10 years earlier than white women, with larger uteri at presentation and 2–3-fold higher prevalence in incidence-matched analyses (Stewart et al. 2017) (Baird et al. 2003). The SELF study, an ultrasound-based prospective cohort of 1,693 young Black women without prior fibroid diagnosis at baseline, established the natural-history baseline for this population and confirmed the earlier-onset signal independent of healthcare access (Baird et al. 2020). Mechanisms remain incompletely understood (genetics, vitamin D status, endocrine-disrupting hair-product exposures, social determinants of health all implicated).

Age. Symptom incidence peaks in the 30s and 40s. Most fibroids regress symptomatically at menopause; new fibroids essentially never form after menopause. A postmenopausal woman with a new or growing pelvic mass needs sarcoma exclusion, not fibroid management.

Reproductive intent. The single biggest treatment-determining variable beyond fibroid location. Hysterectomy is off the table for patients who want pregnancy; UAE is generally off the table; ablation has thinner pregnancy data; myomectomy (preferentially hysteroscopic if feasible) is the workhorse.

practicalities / cost

Annual US economic burden of fibroids is estimated at $5.9–34.4 billion in direct medical costs plus substantial indirect costs through lost productivity (Soliman et al. 2015). Per-patient procedure costs (2014–2015 USD) range hysterectomy $5,000–$8,000, myomectomy $5,400–$11,800, UAE $5,400–$7,600; total direct costs in the year of intervention range $15,878–$21,603 per patient. Indirect costs (lost work, reduced home productivity) add $2,400–$15,500 per affected woman annually. 60% of symptomatic women report quality-of-life impact severe enough to impair physical activity; 24% report it prevents them from reaching potential at work (Soliman et al. 2015). Insurance coverage in the US is generally good for medically necessary fibroid surgery and embolization; emerging therapies like RFA and MRgFUS coverage varies.

stakes

Untreated symptomatic fibroids drag chronic, often unrecognized morbidity. Heavy bleeding produces iron-deficiency anemia in approximately one-third of HMB patients, with fatigue, exercise intolerance, restless legs, hair shedding, pallor, and cognitive fog — symptoms that women and clinicians both routinely misattribute to "just being tired." Bulk symptoms (urinary frequency from anterior subserosal fibroids, constipation from posterior fibroids, abdominal protrusion from a 14-cm uterus) compound social withdrawal and clothing-fit problems. Long-term, untreated HMB-driven anemia compounds with age and can rarely become life-threatening, requiring transfusion. The high prevalence and low recognition explain why fibroids account for 40% of US hysterectomies — many women only present once disease is advanced enough that uterus-sparing treatment is no longer the easiest call (ACOG 2021).

payoff

Treatment-responsive symptoms — particularly HMB — improve dramatically across modalities. Relugolix combination therapy produced ≥50% bleeding reduction in 71–73% of women within 24 weeks (Al-Hendy et al. 2021), with hemoglobin recovery and meaningful UFS-QOL gains. Hysteroscopic myomectomy resolves HMB in ~70–80% of patients with submucosal disease. UAE and myomectomy approximately double quality-of-life scores at 2 years (Manyonda et al. 2020). After menopause, untreated fibroids typically regress and become asymptomatic; observation is a legitimate strategy for women within a few years of expected menopause whose anemia is manageable.

out-of-scope

Adenomyosis (smooth muscle within the endometrium) is frequently co-existent and confused with fibroids on imaging; its management overlaps but is not identical. Endometriosis is a separate entity with separate pathophysiology and treatment despite some symptom overlap. Heavy menstrual bleeding from non-fibroid causes (coagulopathy, ovulatory dysfunction, endometrial polyps, hyperplasia, malignancy — the FIGO PALM-COEIN framework). Sarcoma surveillance after morcellation. Hormone replacement therapy in postmenopausal women with prior fibroids (generally safe; fibroids do not typically regrow on standard HRT doses).

Credibility range

Optimist case

Modern fibroid medicine is a success story. A single condition that 25 years ago meant either hysterectomy or untreated misery now has a layered menu: non-hormonal tranexamic acid for the bleeding-only case, an oral once-daily GnRH antagonist combination with phase 3 RCT evidence for the medically managed case (Al-Hendy et al. 2021) (Schlaff et al. 2020), hysteroscopic resection for the submucosal case, embolization for the uterus-sparing bulky case with a decade of follow-up showing two-thirds of patients avoiding hysterectomy (de Bruijn et al. 2016), and hysterectomy as a definitive option that genuinely cures. FIGO classification gives clinicians a shared language. ACOG 2021 guidance is current and concrete (ACOG 2021). Even imaging is good: TVUS is accurate, sonohysterography reaches near-perfect discrimination of submucosal disease, MRI maps anatomy for surgical planning. The literature is large, the trials are real, and the patient-priority-matched decision tree works.

Skeptic case

Reality is messier. Hysterectomy still accounts for the plurality of fibroid treatments in the US, suggesting the uterus-sparing menu doesn't reach everyone, especially in disadvantaged populations. Racial disparities are enormous and not just biological — Black women present later, with larger fibroids, and receive hysterectomy disproportionately even after adjustment for disease severity. Long-term safety data on GnRH antagonist combinations is still only 1–2 years; bone density worries linger. Ulipristal acetate, briefly the great hope for non-surgical management, was effectively withdrawn over hepatotoxicity. Reintervention rates after UAE are non-trivial (15–30% over 5–10 years). The fertility-after-myomectomy literature is dominated by small observational studies. The leiomyosarcoma morcellation episode reshaped surgical practice for what may be a fairly rare event but a devastating one when missed. And the underlying biology — why some fibroids stay tiny and asymptomatic while others grow to fill the pelvis — remains poorly predictive at the individual level.

Author's call

This entry treats fibroids as a real, common, manageable condition rather than as an inevitable nuisance of being female. The bleeding phenotype is the most important to recognize because it drives anemia that nearly everyone normalizes and almost no one likes; the modern medical menu (LNG-IUS, tranexamic acid, GnRH antagonist combos) is good and underused. Bulk-symptom disease is where the surgical/interventional menu matters most; the right answer depends almost entirely on reproductive intent and fibroid location, which means a thoughtful initial workup with imaging — and a clinician who reads it — is the highest-leverage step. Controversy on individual approaches (UAE vs. myomectomy, when to use morcellation) is real but second-order; the bigger gap is awareness and access, not technology.

Stakeholder and incentive map

Gynecologic surgeons push toward myomectomy and hysterectomy — the traditional bread-and-butter procedures with the best long-term outcome data and the highest reimbursement.
Interventional radiologists push UAE, with a competitive ecosystem around UFE marketing; the FEMME trial complicated their pitch but the EMMY 10-year data supports it as a hysterectomy-avoidance tool.
Device manufacturers (Acessa/Hologic for RFA, InSightec for MRgFUS) push uterus-sparing thermal ablation; trial data is real but shorter-horizon than the surgical alternatives.
Pharmaceutical industry — Myovant/Pfizer (relugolix combo), AbbVie (elagolix combo), Theramex (linzagolix) drove the GnRH antagonist combo wave with phase 3 trials. All approved drugs are off-patent expensive ($800–$1,000+/month in the US without insurance).
Patient advocacy — White Dress Project, USA Fibroid Centers, and Black-women-focused organizations have raised awareness of disparities and demanded earlier access to uterus-sparing care.
Regulators — FDA's 2014 power morcellator warning reshaped the surgical landscape; ACOG's 2021 bulletin codified the medical-then-surgical framework (ACOG 2021).

Population variability

Race. Black women: earlier onset (~10 years), larger uteri, more multiple fibroids, more symptoms, higher hysterectomy rate, lower uterus-sparing surgery rate (Baird et al. 2003) (Baird et al. 2020).
Family history. First-degree relative with fibroids approximately doubles risk; HLRCC syndrome (germline FH mutation) presents with multiple early-onset fibroids and renal cell carcinoma risk and warrants genetic counseling.
Parity. Each term pregnancy after age 25 reduces risk; nulliparity is associated with higher prevalence.
Obesity and metabolic syndrome. Higher BMI and insulin resistance associated with fibroid risk, plausibly via increased aromatization of androgens to estrogens in adipose tissue.
Vitamin D. Deficiency associated with higher prevalence in observational data; small RCTs of supplementation showed modest fibroid-volume effects. Mechanistic plausibility (vitamin D inhibits leiomyoma cell proliferation) supports the association but causal evidence is thin.
Alcohol. Beer specifically associated with higher fibroid risk in cohort data; caffeine not consistently associated.
Reproductive stage. Premenopausal women are the at-risk population; pregnancy growth is biphasic (rapid early, slower later); menopause produces gradual regression in white women, slower in Black women.

Knowledge gaps

Why some fibroids stay 1 cm asymptomatic and others reach 15 cm symptomatic remains poorly predictable from genotype, hormones, or imaging at presentation.
Long-term (5+ year) safety of GnRH antagonist combos is still being characterized, particularly for bone density and cardiovascular endpoints.
The fertility-and-pregnancy outcomes after UAE, RFA, and MRgFUS are not well-characterized in RCTs; clinical practice errs toward myomectomy when pregnancy is the immediate goal, but the data gap is real.
Whether earlier intervention in mildly symptomatic Black women (the highest-burden group) would meaningfully reduce eventual hysterectomy rates is the single most important practical question and has no RCT answer.
Non-hormonal, oral, fibroid-shrinking drugs without GnRH-axis suppression remain an unmet need; the failure of ulipristal acetate left the field without a clean SPRM option.
Dietary and environmental risk modification (vitamin D, EDCs, weight) is supported by observational signal and biological plausibility but lacks intervention-trial evidence on incidence prevention.

Scoping calls

The brief named bleeding, pelvic pressure, fertility, and pregnancy outcomes as consequences, plus management variation by location and patient priorities. The article covers all four consequences (bleeding in evidence, protocol, stakes; pressure in stakes, protocol; fertility and pregnancy in audience) and frames the management menu around the location-and-priorities axis explicitly in protocol. No silent narrowing.

The audience addressing section does double duty — pregnancy/fertility and Black-women-specific disease. Both are audience-scoped content; combining them avoided two near-duplicate sections and let the disparities story sit alongside the fertility decision tree where it actually lives in clinical practice. Worth flagging because if the disparities content grows in future revisions it may justify its own ad-hoc section.

Rating difficulties

Beauty dimensions (1/1). Genuinely indirect — visible abdominal protrusion from bulky disease and anemia-driven pallor/hair changes are real but secondary to the underlying bleeding/bulk phenotype. Rated low rather than zero because the visible-belly complaint is common enough in symptomatic cases to count. Did not go higher because it's not what brings most women in.
Longevity (1). Fibroids are not directly lethal. The 1 captures rare deaths from severe anemia or from morcellation of an occult sarcoma. A 0 would have understated the morcellation issue; anything above 1 would have overstated the actual mortality signal.
Energy/focus/sleep/mood. All scored through the iron-deficiency-anemia and HMB-quality-of-life pathway. Energy got a 3 because the felt-fatigue effect of HMB-driven anemia is large and routinely under-recognized. Focus, sleep, mood are lower because the effects are real but more diffuse and the literature is downstream (iron repletion → cognition, RLS, etc.) rather than direct fibroid → outcome.
Evidence (5). The fibroid literature is genuinely Cochrane-level for medical and procedural management — LIBERTY 1/2, Elaris UF-1/2, PRIMROSE 1/2, FEMME, EMMY, plus current ACOG and ASRM guidelines. The 5 is defensible even by the spec's "name 2+ rigorous trials" bar.
Controversy (2). Lower than it might feel from inside the field — there is broad consensus on diagnosis, on the medical-then-surgical ladder, on hysterectomy as definitive. The active debates (UAE vs. myomectomy ranking, morcellation, racial disparity in treatment selection) are real but not paradigm-level.

Excluded topics — and why

Sarcoma surveillance after morcellation. Addressed briefly in failure-modes and misconceptions; the deeper postoperative-surveillance workflow is its own topic and warrants a separate entry.
Detailed surgical technique comparisons (robotic vs. straight-laparoscopic myomectomy, single-port approaches). Beyond what a non-clinician reader needs; the location-and-priorities framework is the right altitude.
Mifepristone, ulipristal acetate, and other SPRMs. Ulipristal was effectively withdrawn over hepatotoxicity; mifepristone is off-label and not in mainstream US practice for fibroids. Mentioned in research dossier credibility range but not in article body, which would have confused the current-options story.
Endocrine-disrupting chemicals and hair products. Real signal in the disparities literature but actively researched without intervention-trial evidence; would have stretched the article into prevention territory the body doesn't otherwise cover.
Vitamin D supplementation as prevention/treatment. Observational signal plus mechanistic plausibility plus thin RCT data on volume reduction. Mentioned in research dossier knowledge gaps; held out of the article because "take vitamin D for your fibroids" overstates the evidence.

Future-link candidates

heavy-menstrual-bleeding — sibling entry that this one repeatedly forward-references; should land in the same wave.
iron-deficiency-anemia — the downstream consequence that ties the energy/focus/mood scores together.
endometriosis, adenomyosis — frequently co-existent, frequently confused, separate management.
hysterectomy — the procedure itself as a decision (oophorectomy or not, vaginal vs. abdominal vs. laparoscopic) deserves a separate entry given how many entries will link to it.
menopause-hormone-therapy — needed for the "after menopause, what about HRT?" question this entry deliberately leaves to out-of-scope.

Separate-entry candidates

Uterine artery embolization — interventional-radiology procedures cut across several gynecology topics (fibroids, adenomyosis, postpartum hemorrhage) and arguably deserve their own entry once those exist.
Power morcellation and occult sarcoma — touched here but the FDA history, contained-morcellation technique, and the surgical-decision impact are a story big enough to break out.